{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:46:20Z","timestamp":1771955180304,"version":"3.50.1"},"reference-count":61,"publisher":"Scientific Scholar","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>The endothelium is one of the most important constituents of vascular homeostasis, which is achieved through continual and balanced production of different relaxing and contractile factors. When there is a pathological disturbance in release of these products, endothelial dysfunction (ED) will probably occur. ED is considered to be the initial step in the development of atherosclerosis. This pathological activation and inadequate functioning of endothelial cells was shown to be to some extent a reversible process, which all together resulted in increased interest in investigation of different beneficial treatment options. To this point, the pharmacological approach, including for example, the use of angiotensin-converting enzyme inhibitors or statins, was clearly shown to be effective in the improvement of ED. One of many critical issues underlying ED represents instability in the balance between nitric oxide and angiotensin II (Ang II) production. Considering that Ang II was confirmed to be important for the development of ED, the aim of this review article was to summarize the findings of up to date clinical studies associated with therapeutic application of angiotensin receptor blockers and improvement in ED. In addition, it was of interest to review the pleiotropic actions of angiotensin receptor blockers linked to the improvement of ED. The prospective, randomized, double-blind, placebo or active-controlled clinical trials were identified and selected for the final evaluation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/0971-5916.195022","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T09:44:36Z","timestamp":1481535876000},"page":"154-168","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Angiotensin receptor blockers &amp; endothelial dysfunction"],"prefix":"10.25259","volume":"144","author":[{"given":"Miroslav","family":"Radenkovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Stojanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana Mili\u0107evi\u0107","family":"Ne\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Prostran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"R1-3-20241212","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2840-5-4","article-title":"Endothelial dysfunction: a comprehensive appraisal","volume":"5","author":"Esper","year":"2006","journal-title":"Cardiovasc Diabetol"},{"key":"R2-3-20241212","first-page":"1121","article-title":"Endothelial function and atherosclerosis: circulatory markers with clinical usefulness","volume":"28","author":"Ribeiro","year":"2009","journal-title":"Rev Port Cardiol"},{"key":"R3-3-20241212","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1139\/y2012-073","article-title":"The endothelium: influencing vascular smooth muscle in many ways","volume":"90","author":"Triggle","year":"2012","journal-title":"Can J Physiol Pharmacol"},{"key":"R6-3-20241212","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3797\/scipharm.1305-13","article-title":"Pharmacological analysis of the rat femoral artery response to bradykinin","volume":"81","author":"Radenkovic","year":"2013","journal-title":"Sci Pharm"},{"key":"R7-3-20241212","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0306-3623(01)00087-8","article-title":"Characterization of adenosine action in isolated rat renal artery. Possible role of adenosine A(2A) receptors","volume":"35","author":"Grbovic","year":"2000","journal-title":"Gen Pharmacol"},{"key":"R8-3-20241212","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1734-1140(12)70846-0","article-title":"L-NAME in the cardiovascular system \u2013 Nitric oxide synthase activator?","volume":"64","author":"Kopincov\u00e1","year":"2012","journal-title":"Pharmacol Rep"},{"key":"R9-3-20241212","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5830\/CVJA-2011-068","article-title":"Endothelial dysfunction: the early predictor of atherosclerosis","volume":"23","author":"Mudau","year":"2012","journal-title":"Cardiovasc J Afr"},{"key":"R10-3-20241212","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bjp.0706042","article-title":"Endothelium-dependent contractions in hypertension","volume":"144","author":"Vanhoutte","year":"2005","journal-title":"Br J Pharmacol"},{"key":"R11-3-20241212","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1139\/Y08-023","article-title":"Expression of human endothelin-converting enzyme isoforms: role of angiotensin II","volume":"86","author":"Goettsch","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"key":"R12-3-20241212","first-page":"529","article-title":"The physiological significance of the alternative pathways of angiotensin II production","volume":"57","author":"Kramkowski","year":"2006","journal-title":"J Physiol Pharmacol"},{"key":"R13-3-20241212","first-page":"64","article-title":"Pharmacological evaluation of bradykinin effect on human umbilical artery in normal, hypertensive and diabetic pregnancy","volume":"59","author":"Radenkovic","year":"2007","journal-title":"Pharmacol Rep"},{"key":"R14-3-20241212","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1734-1140(09)70095-7","article-title":"Altered response of human umbilical artery to 5-HT in gestational diabetic pregnancy","volume":"61","author":"Radenkovic","year":"2009","journal-title":"Pharmacol Rep"},{"key":"R15-3-20241212","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijcard.2010.10.011","article-title":"Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients","volume":"155","author":"Geng","year":"2012","journal-title":"Int J Cardiol"},{"key":"R16-3-20241212","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1345\/aph.1M312","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines","volume":"44","author":"Gales","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R17-3-20241212","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1536\/jhj.45.623","article-title":"A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension","volume":"45","author":"Leu","year":"2004","journal-title":"Jpn Heart J"},{"key":"R18-3-20241212","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.ATV.0000022847.38083.B6","article-title":"Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction","volume":"22","author":"Wassmann","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-3-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R20-3-20241212","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1161\/01.CIR.101.14.1653","article-title":"Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan","volume":"101","author":"Schiffrin","year":"2000","journal-title":"Circulation"},{"key":"R21-3-20241212","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/01.ATV.0000187465.55507.85","article-title":"Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans","volume":"25","author":"Watanabe","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R22-3-20241212","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3317\/jraas.2003.032","article-title":"Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients","volume":"4","author":"Yavuz","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R23-3-20241212","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ajh\/hpt208","article-title":"Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension","volume":"27","author":"Suzuki","year":"2014","journal-title":"Am J Hypertens"},{"key":"R24-3-20241212","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1751-7176.2009.00108.x","article-title":"Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease","volume":"11","author":"Perrone-Filardi","year":"2009","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R25-3-20241212","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/eurheartj\/ehm101","article-title":"Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients","volume":"28","author":"Koh","year":"2007","journal-title":"Eur Heart J"},{"key":"R26-3-20241212","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2008.11.017","article-title":"Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs","volume":"140","author":"Koh","year":"2010","journal-title":"Int J Cardiol"},{"key":"R27-3-20241212","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1177\/147323000903700403","article-title":"Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients","volume":"37","author":"Sozen","year":"2009","journal-title":"J Int Med Res"},{"key":"R28-3-20241212","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1524-6175.2006.05663.x","article-title":"Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade","volume":"8","author":"Souza-Barbosa","year":"2006","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R29-3-20241212","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijcard.2011.10.099","article-title":"Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study","volume":"155","author":"Vitale","year":"2012","journal-title":"Int J Cardiol"},{"key":"R30-3-20241212","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2337\/db06-0827","article-title":"Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy","volume":"55","author":"Persson","year":"2006","journal-title":"Diabetes"},{"key":"R31-3-20241212","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.CIR.0000153272.48711.B9","article-title":"Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and lipoic acid in endothelial dysfunction (ISLAND) study","volume":"111","author":"Sola","year":"2005","journal-title":"Circulation"},{"key":"R32-3-20241212","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.atherosclerosis.2006.08.034","article-title":"AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease","volume":"194","author":"Warnholtz","year":"2007","journal-title":"Atherosclerosis"},{"key":"R33-3-20241212","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2337\/dc06-1551","article-title":"Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes","volume":"30","author":"Schmieder","year":"2007","journal-title":"Diabetes Care"},{"key":"R34-3-20241212","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/HYPERTENSIONAHA.110.169193","article-title":"Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration","volume":"58","author":"Endtmann","year":"2011","journal-title":"Hypertension"},{"key":"R35-3-20241212","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00392-010-0184-0","article-title":"Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease","volume":"99","author":"Zankl","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"R36-3-20241212","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jcin.2011.09.022","article-title":"Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients","volume":"5","author":"Terashima","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"R37-3-20241212","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1536\/ihj.51.252","article-title":"Fixed-dose telmisartan\/hydrochlorothiazide in comparison with losartan\/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients","volume":"51","author":"Hu","year":"2010","journal-title":"Int Heart J"},{"key":"R38-3-20241212","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijcard.2008.10.048","article-title":"Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance","volume":"139","author":"Perl","year":"2010","journal-title":"Int J Cardiol"},{"key":"R39-3-20241212","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1755-5922.2009.00085.x","article-title":"Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study","volume":"27","author":"Tzemos","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"R40-3-20241212","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/10641960802071000","article-title":"Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension","volume":"30","author":"Hirooka","year":"2008","journal-title":"Clin Exp Hypertens"},{"key":"R41-3-20241212","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/FJC.0b013e31802b31a7","article-title":"Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes","volume":"49","author":"Willemsen","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"R42-3-20241212","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2215\/CJN.01110210","article-title":"Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation","volume":"5","author":"Yilmaz","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R43-3-20241212","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejim.2011.11.011","article-title":"The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial","volume":"23","author":"Lunder","year":"2012","journal-title":"Eur J Intern Med"},{"key":"R44-3-20241212","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1093\/ndt\/gfr108","article-title":"Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis","volume":"26","author":"Han","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R45-3-20241212","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.HYP.0000159191.98140.89","article-title":"Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists","volume":"45","author":"Bahlmann","year":"2005","journal-title":"Hypertension"},{"key":"R46-3-20241212","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1755-5949.2012.00304.x","article-title":"Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients","volume":"18","author":"Wei","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"R47-3-20241212","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5152\/akd.2014.4793","article-title":"Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study","volume":"14","author":"Sendur","year":"2014","journal-title":"Anadolu Kardiyol Derg"},{"key":"R48-3-20241212","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/hr.2014.81","article-title":"A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation","volume":"37","author":"Takagi","year":"2014","journal-title":"Hypertens Res"},{"key":"R49-3-20241212","doi-asserted-by":"crossref","first-page":"E90217","DOI":"10.1371\/journal.pone.0090217","article-title":"Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"R50-3-20241212","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1470320313487567","article-title":"Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats","volume":"16","author":"Segersv\u00e4rd","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R51-3-20241212","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000328632","article-title":"ARB treatment prevents the decrease in endothelial progenitor cells and the loss of renal microvasculature in remnant kidney","volume":"33","author":"Yu","year":"2011","journal-title":"Am J Nephrol"},{"key":"R52-3-20241212","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1074248412463966","article-title":"Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas","volume":"18","author":"Lunder","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R53-3-20241212","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1291\/hypres.30.1119","article-title":"Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect","volume":"30","author":"Yao","year":"2007","journal-title":"Hypertens Res"},{"key":"R54-3-20241212","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0735-1097(03)00846-5","article-title":"Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients","volume":"42","author":"Koh","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R55-3-20241212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ajh.2007.5","article-title":"Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension","volume":"21","author":"Yu","year":"2008","journal-title":"Am J Hypertens"},{"key":"R56-3-20241212","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1476-5381.2009.00417.x","article-title":"Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR: LA-cp rats","volume":"158","author":"Russell","year":"2009","journal-title":"Br J Pharmacol"},{"key":"R57-3-20241212","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3797\/scipharm.1407-16","article-title":"Pioglitazone and endothelial dysfunction: pleiotropic effects and possible therapeutic implications","volume":"82","author":"Radenkovic","year":"2014","journal-title":"Sci Pharm"},{"key":"R58-3-20241212","doi-asserted-by":"crossref","first-page":"E96948","DOI":"10.1371\/journal.pone.0096948","article-title":"Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells","volume":"9","author":"Myojo","year":"2014","journal-title":"PLoS One"},{"key":"R59-3-20241212","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1161\/ATVBAHA.111.232058","article-title":"Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan","volume":"31","author":"Knorr","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R60-3-20241212","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/ATVBAHA.112.300985","article-title":"Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival","volume":"33","author":"Siragusa","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R61-3-20241212","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/CH-2011-1394","article-title":"Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-\u03b1","volume":"48","author":"Cicha","year":"2011","journal-title":"Clin Hemorheol Microcirc"},{"key":"R62-3-20241212","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2008.12.036","article-title":"Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K\/Akt pathway","volume":"205","author":"Honda","year":"2009","journal-title":"Atherosclerosis"},{"key":"R63-3-20241212","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/VHRM.S3141","article-title":"Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil","volume":"5","author":"Ferrario","year":"2009","journal-title":"Vasc Health Risk Manag"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201644020-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:58:05Z","timestamp":1751497085000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/angiotensin-receptor-blockers-endothelial-dysfunction-possible-correlation-therapeutic-implications\/"}},"subtitle":["Possible correlation &amp; therapeutic implications"],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0971-5916.195022","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}